🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for ESCC

Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC) NCT07627347NA1 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: anlotinib+bevacizumab Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC NCT05738434Phase 21 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib, Camrelizumab+Chemotherapy→Camrelizumab A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors NCT04686682Phase 1, Phase 21 site📍 Tianjin Jacobio Pharmaceuticals Co., Ltd. · Tests: JAB-8263, JAB-8263 A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) NCT07863141Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: anlotinib + PD-1 inhibitor, PD-1 inhibitor Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC NCT07403136Phase 21 site📍 Shanghai Fudan University · Tests: Vebrekotuzumab, PD-1 antibody Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07559045Phase 21 site📍 Zunyi Second Affiliated Hospital of Zunyi Medical University · Tests: Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Con… Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC NCT07177794Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: toripalimab, capecitabine Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma NCT06912074Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Induction chemoimmunotherapy, Hypofractionated Radiation Therapy, Conventional Fractionated Radiation Therapy, Concurre… Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC NCT07038629Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: S1, Iparomlimab, Radiation Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma NCT07266363n/a1 site📍 Monrovia City of Hope Medical Center · Tests: Small RNA sequencing of exo- and cf-miRNAs, RT-qPCR quantification of cf- and exo-miRNAs (SYNERGY assay), PCR-based val… A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma NCT07484724Phase 21 site📍 Beijing Shanghai Junshi Bioscience Co., Ltd. · Tests: JS212, JS001, 5-FU Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC NCT06510660Phase 21 site📍 Fuzhou Fujian Medical University Union Hospital · Tests: adebrelimab Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites📍 Seoul📍 Seoul📍 Seoul Yuhan Corporation · Tests: YH32364 PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY NCT06354140Phase 21 site📍 Chongqing Daping Hospital and the Research Institute of Surgery of th… · Tests: Tegafur Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer NCT04415853Phase 31 site📍 Beijing Sunshine Lake Pharma Co., Ltd. · Tests: Lerotinib, Irinotecan/Tegafur Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal Cancer NCT07811752Phase 22 sites📍 Shanghai📍 Shanghai Shanghai Chest Hospital · Tests: Sacituzumab Tirumotecan (SKB264) plus Tislelizumab Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma NCT06698692n/a1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Trilaciclib Injection [Cosela] Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma NCT07595770Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy A Study of DB-1310 in Advanced/Metastatic Solid Tumors NCT05785741Phase 1, Phase 224 sites📍 Sacramento📍 Santa Monica📍 Coral Gables DualityBio Inc. · Tests: DB-1310, Trastuzumab, Osimertinib, capecitabine A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors NCT07887971Phase 11 site📍 Miami Aktis Oncology, Inc. · Tests: [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC NCT04973306Phase 2, Phase 31 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: Neoadjuvant Chemoradiotherapy, Tislelizumab, Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended) A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) NCT06709417Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: Sintilimab, Chemotherapy, radiotherapy KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer NCT07481058Phase 21 site📍 Beijing Beijing Konruns Pharmaceutical Co., Ltd. · Tests: KC1036, Toripalimab, Paclitaxel, Cisplatin, KC1036 An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT07080437n/a1 site📍 Chongqing Three Gorges Hospital of Chongqing University · Tests: Immunotherapy Therapy Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma NCT06675201Phase 21 site📍 Chengdu Sichuan University · Tests: neoantigen-loaded dendritic cell vaccine (NeoDC-Vac) TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC NCT06676449Phase 31 site📍 Shanghai Fudan University · Tests: Immunotherapy, chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens, TDLN-sparing RT A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy NCT06769113Phase 21 site📍 Jinan Shanghai Henlius Biotech · Tests: HLX43 Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study NCT06663059Phase 21 site📍 Xi'an Tang-Du Hospital · Tests: Adebrelimab combined with albumin-bound paclitaxel and cisplatin 2 cycle, Adebrelimab combined with albumin-bound pacli… Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma NCT06122493Phase 21 site📍 Shanghai Ruijin Hospital · Tests: Tirelizumab, Nab paclitaxel, Carboplatin, Radiotherapy 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871Phase 1, Phase 25 sites📍 Dothan📍 Grand Rapids📍 Omaha Radiopharm Theranostics, Ltd · Tests: 177Lu-BetaBart, BetaBart + unlabeled BetaBart
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy